peritoneal dialysis patients. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Intervention group: isoflavone supplementation: they will receive, for 8 weeks, two tablets of Soyagol (Goldaru Company) per day, each containing 50 mg of soy isoflavone. Intervention
Sponsors
National Nutrition and Food Technology Research Institute
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Continuous Ambulatory Peritoneal Dialysis for 6 months or more Body mass index (BMI) below 35
Exclusion criteria
Exclusion criteria: Infectious diseases (especially peritonitis) and inflammatory diseases Liver diseases Past medical history of cancer Receiving glucocorticoid drugs, non-steroidal anti-inflammatory drugs Receiving isoflavone supplements Constant consumption of soy or foods containing soy in the diet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum concentrations of lipoprotein(a) [Lp (a)]. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum concentrations of malondialdehyde (MDA). Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum concentrations of high sensitivity c-reactive protein (hs-CRP). Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum concentrations of Soluble intercellular adhesion molecule-1 (sICAM-1). Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum concentrations of bone alkaline phosphatase. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of Osteocalcin. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of N-telopeptide. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of Osteoprotegerin. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of Receptor activator of nuclear factor kappa-? ligand (RANKL). Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of Intact parathyroid hormone (iPTH). Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of triglycerid | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum concentrations of albumin. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Enzymatic assay kit.;Serum concentrations of calcium. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Colorimetric method using autoanalyzer.;Serum concentrations of phosphorous. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Colorimetric method using autoanalyzer.;Blood nitrogen urea. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Colorimetric method.;Creatinine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Colorimetric method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Yari
Shahid Beheshti University of Medical Sciences
Outcome results
None listed